Evidence map›Paper›PMID 38833102›Full record

ArticleFrontiers of medicine2024

Moderate expression of CD39 in GPC3-CAR-T cells shows high efficacy against hepatocellular carcinoma.

Fan Zou, Jialiang Wei, Jialang Zhuang, Yafang Liu, Jizhou Tan, Xianzhang Huang, Ting Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Frontiers of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fan Zou *Guangdong Cardiovsacular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Science, Guangzhou, 510080, China.
Jialiang Wei *Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China.
Jialang Zhuang *School of Food and Drug, Shenzhen Polytechnic University, Shenzhen, 518055, China.
Yafang LiuThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Department of Laboratory Medicine/State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510120, China.
Jizhou TanDepartment of Stomatology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China. tanjzh3@mail2.sysu.edu.cn.
Xianzhang HuangThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Department of Laboratory Medicine/State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510120, China. huangxz020@163.com.
Ting LiuThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Department of Laboratory Medicine/State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510120, China. liuting@gzucm.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD39 serves as a crucial biomarker for neoantigen-specific CD8

Indexed as

ApyraseCarcinoma, HepatocellularGlypicansImmunotherapy, AdoptiveLiver NeoplasmsReceptors, Chimeric AntigenAnimalsAntigens, CDCell Line, TumorHumansMiceXenograft Model Antitumor AssaysAntigens, CDApyraseENTPD1 protein, humanGlypicansGPC3 protein, humanReceptors, Chimeric Antigenantitumor activityCAR-T cellsCD39hepatocellular carcinomamdivi-1

Identifiers

PMID38833102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.